Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$136.46M$136.46M+147.1% vs Q2 2020 Net Income$91.46M$91.46M+254.3% vs Q2 2020 EPS Diluted$0.62$0.62+226.3% vs Q2 2020 Operating Income$93,047,000+214.8% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$36,356,000+1,208.2% Margins · derivedOperating margin68.2%+14.7 pt vs Q2 2020
Net margin67.0%+20.3 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 9, 2021 · 40 d after period end